To understand the regulatory activities of kinases in vivo requires their study across a biologically relevant window of activity. To this end, ATP analog-sensitive kinase alleles (ASKAs) specifically sensitive to a competitive inhibitor have been developed. This article tests whether ASKA technology can be applied to complex immunological systems, such as lymphoid development. T he pivotal role of kinases in biology is clear (1, 2). Nonetheless, we are often ignorant of their biologically relevant substrates and the quantitative window of kinase activity required to phosphorylate them. It is seldom clear when biological processes have graded responses to kinase dosage or "all-or-nothing" responses to thresholds of kinase activity, and thus it is difficult to predict the effect of modest differences in kinase activity that will characterize human genetic variation.
T he pivotal role of kinases in biology is clear (1, 2) . Nonetheless, we are often ignorant of their biologically relevant substrates and the quantitative window of kinase activity required to phosphorylate them. It is seldom clear when biological processes have graded responses to kinase dosage or "all-or-nothing" responses to thresholds of kinase activity, and thus it is difficult to predict the effect of modest differences in kinase activity that will characterize human genetic variation.
An improved understanding ideally requires a capacity to regulate specific kinase activities within complex mammalian systems. In this regard, a recent technological innovation described ATP analog-sensitive kinase alleles (ASKAs) 4 that can accommodate ATP and function normally, but that additionally have high affinity for large ATP analogs, such as 4-amino-1-tert-butyl-3-(1Ј-naphthyl)pyrazolo [3,4-d] pyrimidine (NaPP1), that compete for entry into the ATP binding site (3, 4) . By contrast, the active site of natural kinases is too small to accommodate such inhibitors (3) (Fig. 1a) . Thus, ASKA technology theoretically permits one to regulate the biological effects of any chosen kinase.
This notwithstanding, the application of ASKA technology to complex mammalian biology faces potentially serious uncertainties. These include the expression levels of ASKAs achievable in primary cells and whether the doses of inhibitor needed to gain access to relevant cells within a multicellular organ cause nonspecific biological dysregulation: in sum, will the achievable expression levels of the ASKAs and the practical concentrations of inhibitor combine to regulate kinase activity across a biologically relevant range? To resolve these issues, this article examines the practicality of ASKA technology for studying T cell development in reaggregate fetal thymic organ culture (RTOC).
Stages of thymocyte development are readily marked by CD4 and CD8 expression (5) . Early CD4 Ϫ CD8 Ϫ "double-negative" (DN) thymocytes mature into CD8 low cells (immature singlepositive cells (ISPs)) that become CD4CD8 double-positive (DP) (6) , and finally CD4 ϩ or CD8 ϩ single-positive (SP) cells. The DN-ISP-DP transition depends on the TCR ␤-chain contributing to a pre-TCR (7-9), while the DP-SP transition depends on TCR␤ contributing to a mature ␣␤ TCR. The pre-TCR and TCR␣␤ are each associated with the src-related kinases, Lck and Fyn (10 -12).
Several lines of transgenic and gene knockout mice have indicated that the pre-TCR-dependent DN-ISP-DP transition is inhibited by Lck overexpression as well as by Lck deficiency or expression of a dominant-negative Lck (13-15). Nonetheless, conclusions are inevitably complicated by variability in the onset and durability of Lck transgene expression in the different mouse strains and by the uncertain relationship between Lck expression and Lck activity. Instead, it would be useful to show that different biological effects occur within a single system as Lck activity is incrementally altered across a continuous range.
This seemed an ideal context in which to test the application of ASKA technology to a complex immunological process.
Materials and Methods

Retroviral infections
Lck alleles generated using QuikChange Site-directed mutagenesis (Stratagene, La Jolla, CA) were subcloned into the pMX vector (16) . Briefly, 2 ϫ 10 6 phoenix-E packaging cells were transfected with 20 g of vector DNA in CaCl 2 and 2ϫ HBS (pH 7.05). Medium was changed 8 h after infection, and supernatant viral particles were harvested at 48, 72, and 96 h, passed through 45-m filters; aliquoted, and stored at Ϫ70°C (17).
RTOC, transduction, and formation
Embryonic thymocytes and stromal cells were isolated and prepared as described previously (18) . E14 thymocytes were centrifuged at 2100 rpm for 1 h, incubated with virus for 3 h, and pelleted by centrifugation with thymic epithelial cells at a ratio of 1:3. The resultant slurry was transferred by a finely drawn glass pipette to the surface of a 0.8-m nucleopore filter (19) . Cultures were harvested at indicated times and thymocytes were released from reaggregates using fine cataract knives.
Transduction and Western blot of thymoma BW5147
Briefly, 1.2 ϫ 10 6 cells were transduced with control vector or Lck a -as and, after 48 h, gfp ϩ cells were flow cytometry sorted and expanded in culture with 0, 0.1, 1, 5, or 10 M NaPP1 (Cellular Genomics, Branford, CT) for another 48 h before lysis in Nonidet P-40 buffer. One hundred micrograms of protein lysate was separated on 10% SDS gels, blotted onto nylon membranes, and probed using Abs against total Lck (Santa Cruz Biotechnology, Santa Cruz, CA) and phosphorylated Ysrc416 (Cell Signaling, Beverly, MA), respectively. (Fig. 1a) , an allele predicted to bind ATP and function as a normal tyrosine kinase (20, 21) , but that should also accommodate NaPP1, an enlarged analog of the Src family kinase inhibitor PP1 that competes with ATP for entry into the ATP binding site (3). Other naturally occurring kinases contain a large amino acid corresponding to T316 that precludes NaPP1. Following construction of Lck-as, we combined the T316 G mutation in cis with a Y505 F mutation (Lck a ) that renders Lck constitutively active (22) , to create Lck a -as A primary activity of Lck is autophosphorylation. To test Lck a -as activity, several T cell lines were transduced with retroviruses expressing Lck a -as from a polycistronic RNA also encoding gfp from an internal ribosome entry site. Following transduction, cells were incubated for 48 h in different NaPP1 concentrations, after which equal amounts of gfp ϩ cell lysates were Western blotted and probed with Abs for either total p56
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Lck (Fig. 1b) or Y394-phosphorylated Lck (Fig. 1c) . As the inhibitor was increased, total Lck was comparably expressed (serving as a control for protein loading), whereas phosphorylated p56
Lck decreased in amount in a dose-dependent fashion. Thus, Lck a -as encodes a novel form of Lck, the activity of which is regulatable with NaPP1. Fig. 2a ; in all plots, the x-axis depicts CD8 expression, the y-axis depicts CD4). Although DP development varied from 50% to 82% in different experiments (e.g., because of age variation in the fetuses used as sources of thymocytes and stroma, or variable time of harvest), results within single experiments were more consistent. Moreover, development was largely comparable in nontransduced cultures, "gfp-only" transduced cultures and nontransduced (gfp Ϫ ) cells recovered from RTOC supporting gfp ϩ transduced cells (Fig. 2) . Thus, neither transduction nor gfp expression substantially affects thymocyte development in RTOC.
Consistent with the deleterious effects of Lck overexpression in transgenic mice (15) , gfp ϩ thymocytes transduced with an activated Y505 F Lck allele (Lck a ) showed almost complete inhibition of the DN-DP transition (4% DP), as did Lck a -astransduced thymocytes (Fig. 2a) , thereby demonstrating the ASKA to be biologically equivalent to Lck a . However, the biological activity of Lck a -as was substantially inhibited by addition to the RTOC of 10 M NaPP1. Thus, the inhibitor rescued the generation of DPs (40%) and the expression by many of them of low levels of CD3 (Ͼ23% compared with 18% in controls; Fig. 2a) . The inhibitor's specificity was evident in its failure to rescue RTOCs expressing Lck a (Fig. 2a) . RTOCs harvested at 9 days also showed strong inhibition of DP maturation by Lck a -as as well as an accumulation of CD8 ϩ ISPs (48%), previously associated with Lck overexpression (15) . Both effects were substantially reversed by 10 M NaPP1 (Fig. 2b) . In sum, the combined use of a novel Lck ASKA and an ATP analog inhibitor provided a simple means to alter the activity of Lck over a biologically relevant range within a complex organ culture.
The inhibitory effect of activated Lck is poorly understood, but it is not readily attributed to apoptosis since transgenic mice expressing increased levels of wt or activated Lck showed no obvious decrease in thymocyte numbers (15) . Similarly, comparable numbers of gfp ϩ thymocytes were recovered from the gfponly and from the Lck a -as-transduced cultures. The recovery of similar numbers of cells from cultures containing 10 M NaPP1 indicated that inhibitor per se also does not affect cell viability (see Fig. 2a ).
To determine whether T cell development shows a graded or an all-or-nothing threshold response to variation in Lck activity, different doses of inhibitor were added to RTOCs. In this experiment, the representation of DPs in control vector-transduced cultures ranged from 53 to 71%, whereas for Lck a -astransduced cells it was ϳ9% (Fig. 2c) . Increasing NaPP1 gradually reduced Lck overactivity, incrementally restoring DP cells to 11% (0.5 M NaPP1), 20% (2 M), and ϳ45% (10 M) (Fig. 2c) . The development of gfp Ϫ cells from the same RTOC was within the range of the controls (Fig. 2c) and comparable cell yields again suggested that cell viability was not greatly affected by Lck a -as or by 10 M inhibitor (see legends to Figs. 2 and 3) . Thus, the dose-dependent regulation of a Lck ASKA in RTOC readily exposed a quantitative correlation of T cell development with Lck activity across a continuous range. Fig. 2d In sum, the application of ASKA technology permits Lck activity to be regulated over an unprecedentedly broad, biologically relevant range in a complex organ culture.
Lck a -as is biologically active and specifically inhibitable in mutant RTOC
The biological function of Lck a -as was independently assayed in RTOC using thymocytes from RAG1-deficient mice that cannot rearrange TCR␤ genes and therefore cannot undergo DN-ISP-DP maturation (23) . Thus, gfp-only vector-transduced thymocytes remain Ͼ90% DN (Fig. 3a) , whereas enforced Lck expression mimics pre-TCR signaling, promoting the appearance of ISPs and increasing DP representation from 0.2 to 16% (Fig. 3a) . Although transgenic Lck was reported to rescue DP development more fully than this (24) , those studies used a debilitated Lck. Instead, Lck overexpression in transgenic mice led primarily to ISP accumulation (15) . This distortion in thymocyte development was exaggerated in Lck a and Lck a -as-transduced RTOCs in which DP rescue was only 5-7% (Fig. 3a) . However, increasing doses of inhibitor achieved an incremental rescue of Lck a -as-transduced RAG1 Ϫ/Ϫ DPs (13, 31, 37, 43%; Fig. 3b) . Thus, ASKA technology permitted the dose-dependent regulation of thymocyte development by Lck in wt and mutant forms of RTOC.
Chemical genetic complementation of Lck deficiency across a complete range
Finally, the Lck-ASKA was examined for its capacity to complement the defective development of Lck Ϫ/Ϫ thymocytes. Lck Ϫ/Ϫ mice show partial inhibition of the DN-ISP-DP transition (ϳ35% DP cells) because the defect in pre-TCR signaling is partly compensated by fyn (Fig. 4a and Ref 13) . Rather than rescue this deficiency, strong Lck overexpression permitted only 1% DPs, consistent with its inhibition of thymocyte development (Fig. 4d) . However, by selecting for lower gfp expression (lower levels of Lck), DP representation went from 7% ( Fig. 4c) to 27% (Fig. 4b ) and to 47% (Fig. 4a) . However, substantial rescue of DPs (46%) was also achievable among gfp high cells, simply by adding 10 M NaPP1 (Fig. 4d) . Indeed, within a single NaPP1-treated RTOC, the complementation of Lck deficiency was achieved across a full biologic range. Thus, cells gated for "medium" gfp in the presence of inhibitor showed essentially complete rescue (ϳ60% DP; Fig. 4 , b and c), whereas gfp low cells defined thymocytes in which Lck activity was now insufficient, and in which DP representation fell back to 38% (Fig. 4a) .
Excess Lck favors cell activation over differentiation
Although overexpressed Lck inhibits TCR␤ chain gene rearrangement (25) , the inhibition of T cell development in Lckoverexpressing mice does not phenocopy RAG deficiency and its underlying nature has not been fully clarified. There is little evidence for excess apoptosis (see above), and it has been noted in transgenic studies and here that there is an associated increase in ISPs (15) . The higher the Lck expression (gfp high and 0 inhibitor; Fig. 4d ), the greater was ISP accumulation (60%), whereas in the presence of inhibitor, DP representation exceeded ISP representation in all but the gfp low cells (Fig. 4) . Analysis of forward scatter (Fig. 4) and other properties showed that the ISPs are activated blast cells, whereas DPs are mostly smaller and resting. Of note, as Lck activity was gradually increased, the ISPs were more activated, as reflected by increasing forward scatter (600 -750; Fig. 4) . Therefore, increasing Lck activity in early thymocytes appears, at least in part, to skew pre-TCR signaling toward cell activation at the expense of differentiation. This seems consistent with the role of activated Lck in malignancy (22) . The capacity to sort and analyze cells expressing different levels of Lck from ASKA-transduced cells cultured in different inhibitor concentrations now offers the potential to identify protein phosphorylation and/or gene expression patterns that correlate with particular levels of kinase activity and their associated biological outcomes.
In sum, we have combined a novel chemical genetic approach with retroviral transduction of RTOC to achieve rapid and efficient analysis of a kinase playing a crucial role in mammalian cells. Previous study of the dose-dependent effects of Lck on T cell development required the labor-intensive generation of multiple lines of transgenic mice expressing different levels of an Lck transgene (15) . Although those studies provided a firm foundation to validate the use of ASKA as a tool in developmental immunology, it is already clear from Fig. 2d that the range of biological effects of Lck achievable with ASKA technology exceeds that obtained by selecting cells stochastically expressing different levels of a kinase. Indeed, whereas identification of cell lines or transgenic mice expressing a biologically relevant level of a transgene can be problematic, the capacity to use ASKAs to regulate kinase activity may allow one to use mice or cell lines grossly overexpressing a particular kinase. The relative ease of ASKA construction (successfully applied to v-Src, CDK2, Fus3, CAMKII␣ (4)), the specificity of the inhibitor's effects; the broad range of kinase activity achievable, and the closer correlation of biological outcome with kinase activity, as opposed to inducible levels of gene expression (26, 27) suggest that ASKA technology should be usefully applied to many kinases emerging from the expression profiling of lymphoid cells (28, 29) and from genome sequencing.
